MWVC
PCRX icon

Morgens Waterfall Vintiadis & Co’s Pacira BioSciences PCRX Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,500
Closed -$707K – 59
2017
Q1 		$707K Buy
+15,500
New +$670K 0.63% 46

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's PCRX Position: Q2 2017 in Review

Morgens Waterfall Vintiadis & Co sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 15,500 shares — an estimated $707K sold.

Morgens Waterfall Vintiadis & Co first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $707K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Morgens Waterfall Vintiadis & Co reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 15,500 Pacira BioSciences shares in Q2 2017, an estimated $707K.
  • Morgens Waterfall Vintiadis & Co first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Pacira BioSciences position peaked at $707K in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q2 2017, filed 14 Aug 2017.